Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Document series

Trial abstracts — page 27

700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.

Showing 0 records on this page

Trial records

700 documents · page 27 of 30

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
HEX-PH2-ELDERLY-BODY-COMPprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-ELDERLYprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-QOLprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-REGIONAL-CNprogramme recordHexarelinPhase 3ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-REGIONAL-JPprogramme recordHexarelinPhase 3ReportedRandomised, double-blind, placebo-controlled1997Very low
GHRP6-PH1-GH-ADHERENCEprogramme recordGHRP-6Phase 1ReportedObservational1995Very low
GHRP6-PH1-GH-BIOMARKERprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
GHRP6-PH1-GH-ELDERLYprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
GHRP6-PH1-GH-OLEprogramme recordGHRP-6Phase 1ReportedSingle-arm open-label1995Very low
GHRP6-PH1-GH-QOLprogramme recordGHRP-6Phase 1ReportedRandomised, double-blind, placebo-controlled1995Very low
HEX-PH1-GH-DDIprogramme recordHexarelinPhase 1ReportedRandomised crossover1995Very low
HEX-PH1-GH-HEPATIC-IMPprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
HEX-PH1-GH-OLEprogramme recordHexarelinPhase 1ReportedSingle-arm open-label1995Very low
HEX-PH1-GH-PKprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
HEX-PH1-GH-RENAL-IMPprogramme recordHexarelinPhase 1ReportedPhase 1 ascending dose1995Very low
AMY-PH1-ORALprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending doseVery low
AMY-PH1B-SCprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending doseVery low
BPC-PH2-UC-BODY-COMPprogramme recordBPC-157Phase 2ReportedRandomised, double-blind, placebo-controlledVery low
BPC-PH2-UC-QOLprogramme recordBPC-157Phase 2ReportedRandomised, double-blind, placebo-controlledVery low
BPC-PH2-UC-REGIONAL-CNprogramme recordBPC-157Phase 3ReportedRandomised, double-blind, placebo-controlledVery low
BPC-PH2-UC-REGIONAL-JPprogramme recordBPC-157Phase 3ReportedRandomised, double-blind, placebo-controlledVery low
DREAMS-3-BODY-COMPprogramme recordMazdutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
DREAMS-3-REGIONAL-CNprogramme recordMazdutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
DREAMS-3-REGIONAL-JPprogramme recordMazdutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low

page 27 of 30

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.